

Supplementary Table 1. The main biologic agents on market

Drugs	FDA approval time	CFDA approval time	Standard regimen	Half-life
Etanercept	Apr.30, 2004	Jul.23, 2012	50mg twice a week for the first 12 weeks, followed by 50mg weekly	3.5 days
Infliximab	Sept.27, 2006	Aug.22, 2013	5 mg / kg at weeks 0, 2, and 6 and thereafter every 8 weeks	10 days
Adalimumab	Jan.22, 2008	May.17, 2018	80 mg at week 0, 40 mg at week1, and 40 mg every two weeks thereafter.	14 days
Ustekinumab	Sept.25, 2009	Feb.21, 2019	45 mg at week 0 and 4, followed by every 12 weeks. The dosage is 90 mg for patients $\geq 100$ kg.	21 days
Secukinumab	Jan.21, 2015	Apr.1, 2019	300 mg at weeks 0, 1, 2, 3 and 4, and then 300 mg every 4 weeks.	27 days
Ixekizumab	Mar.22, 2016	Sept.4, 2019	160 mg at week 0, 80 mg at 2, 4, 6, 8, 10 and then 80 mg every 4 weeks.	13 days
Brodalumab	Feb.15, 2017	Not approved yet	210 mg at weeks 0, 1 and 2, followed by every 2 weeks.	11 days
Guselkumab	Jul.13, 2017	Dec.27, 2019	100 mg at week 0, week 4, and every 8 weeks thereafter.	18 days
Tildrakizumab	Mar.21, 2018	Not approved yet	100 mg at weeks 0 and 4 and then every 12 weeks.	23 days
Risankizumab	Apr.23, 2019	Not approved yet	150 mg at week 0, week 4, and every 12 weeks thereafter.	11 days